Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / ERAS - Erasca to Present at Upcoming Investor Conferences in June


ERAS - Erasca to Present at Upcoming Investor Conferences in June

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer and chief business officer, will participate in the following investor conferences in June 2024, and will also participate in one-on-one investor meetings.

Jefferies Global Healthcare Conference (June 5 – 6, 2024)
Location: Marriott Marquis, New York, NY
Format: Presentation
Date and Time: Thursday, June 6, 10:30 – 10:55 am Eastern Time

Goldman Sachs 45 th Annual Global Healthcare Conference (June 10 – 13, 2024)
Location: Loews Miami Beach Hotel, Miami Beach, Florida
Format: Fireside Chat
Date and Time: Wednesday, June 12, 10:40 – 11:15 am Eastern Time

A live audio webcast of the events will be available online at Erasca.com/events . An archived replay of the events will be available for 30 days following the webcast at Erasca.com/events .

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We have assembled one of the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Source: Erasca, Inc.


Stock Information

Company Name: Erasca Inc.
Stock Symbol: ERAS
Market: NASDAQ
Website: erasca.com

Menu

ERAS ERAS Quote ERAS Short ERAS News ERAS Articles ERAS Message Board
Get ERAS Alerts

News, Short Squeeze, Breakout and More Instantly...